A Study to Evaluate the Safety, Tolerability and PK of SK-08
Status:
RECRUITING
Trial end date:
2025-08-07
Target enrollment:
Participant gender:
Summary
The trial is conducted in a single-center, randomized, double-blind, placebo-controlled, dose-increasing design. To evaluate the safety, tolerability, pharmacokinetics(PK) ,and pharmacodynamics (PD) characteristics of SK-08 in healthy participants.